Skip to content

Clinical trials

Multiple Chronic Conditions trials in the United States with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Multiple Chronic Conditions Phase: Not applicable Country / region: United States Clear all

43 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20121
20131
20142
20161
20181
20194
20206
20213
20229
20236
20243
20255
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed28
Recruiting6
Active, not recruiting4
Not yet recruiting1
Enrolling by invitation1
Terminated1
Unknown status1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University of Utah4
University of Alabama at Birmingham3
University of North Carolina, Chapel Hill3
VA Office of Research and Development3
Innovation Research & Training2
University Hospitals Cleveland Medical Center2
University of Wisconsin, Madison2
Brigham and Women's Hospital1
Indiana University1
Johns Hopkins University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Multiple Chronic Conditions43
Chronic Disease4
Diabetes Mellitus3
Hypertension3
Dementia2
Leukemia, Lymphocytic, Chronic, B-Cell2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive2
Obesity2
Burnout, Professional1
Cognitive Dysfunction1

Trials

Showing 1 to 25 of 43. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.